HFA Premium Access

REALM-DCM: a phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 (PF-07265803) in patients with symptomatic LMNA-related dilated cardiomyopathy

Congress Presentation

About the speaker

Doctor Roberto Barriales-Villa

Coruna University Hospital Complex, Coruna, A (Spain)
4 presentations
0 follower

5 more presentations in this session

Sodium-glucose cotransporter 2 inhibitors in patients with transthyretin amyloid cardiomyopathy - results from a patient series

Speaker: Doctor J. Brito (Lisbon, PT)


Trace element equilibrium in acute heart failure and the effect of empagliflozin

Speaker: Assistant Professor N. Bomer (Groningen, NL)


Efficacy and safety of sacubitril-valsartan in heart failure with reduced ejection fraction in end-stage renal patients.

Speaker: Doctor R. Rascon Sabido (Veracruz, MX)


Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction

Speaker: Doctor J. Youn (Seoul, KR)


Short-term changes in hemoglobin and changes in functional status, quality of life, and natriuretic peptides after initiation of dapagliflozin in heart failure with reduced ejection fraction

Speaker: Doctor M. Amiguet Comins (Castellon de la Plana, ES)


Access the full session

Chronic heart failure - pharmacotherapy 5

Speakers: Doctor R. Barriales-Villa, Doctor J. Brito, Assistant Professor N. Bomer, Doctor R. Rascon Sabido, Doctor J. Youn...

About the event


Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

ESC 365 is supported by